TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.
TOLREMO therapeutics has raised $37.9M in total funding. The most recent round was Series A. The last funding was announced in September 2023.
TOLREMO therapeutics's investors include Zúrcher Kantonal Bank, Altos Ventures, redalpine, BioMedPartners, Pierre Fabre Invest.
TOLREMO therapeutics is headquartered in Zúrich, Switzerland.
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.
TOLREMO therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TOLREMO therapeutics — Funding & Investors." VCBacked, September 20, 2023, https://www.vcbacked.co/company/tolremo-therapeutics. Accessed September 15, 2026.
VCBacked. (2023). TOLREMO therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/tolremo-therapeutics
{{cite web |title=TOLREMO therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tolremo-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated